ARCHIVES

Gene Variant Associated With 44 Percent Cancer Risk Reduction

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

NIC Grants Appeals Process Explained

April 19, 1985

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

March 29, 2013

Proflavine Bioassay Ineffective, NCI Says

July 15, 1977

CT Scan Can Spare Surgery In Head And Neck Cancer

November 25, 2005

In Brief: Katterhagen Committee to Meet On PDQ Questions; ACS Grants Total Highest In History, $57 Million

August 19, 1983

NY Attorney General Subpoenaes Amgen, J&J Over ESA Promotion.

May 25, 2007